{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:09:15Z","timestamp":1791216555123,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T00:00:00Z","timestamp":1452297600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40268-015-0120-x","type":"journal-article","created":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T12:36:07Z","timestamp":1452342967000},"page":"93-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies"],"prefix":"10.1007","volume":"16","author":[{"given":"P.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brealey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Surry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Severin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Elsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,9]]},"reference":[{"key":"120_CR1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/dmd.110.032151","volume":"38","author":"DJ Sweeny","year":"2010","unstructured":"Sweeny DJ, Li W, Clough J, et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos. 2010;38:1166\u201376.","journal-title":"Drug Metab Dispos."},{"key":"120_CR2","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/art.23992","volume":"58","author":"ME Weinblatt","year":"2008","unstructured":"Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58:3309\u201318.","journal-title":"Arthritis Rheum."},{"key":"120_CR3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.30114","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63:337\u201345.","journal-title":"Arthritis Rheum."},{"key":"120_CR4","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3899\/jrheum.140238","volume":"41","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, van der Heijde DM, Keystone EC, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-alpha antagonist. J Rheumatol. 2014;41:2120\u20138.","journal-title":"J Rheumatol."},{"key":"120_CR5","doi-asserted-by":"crossref","unstructured":"Taylor PC, Genovese MC, Greenwood M, et al. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2014 (Epub ahead of print).","DOI":"10.1136\/annrheumdis-2014-205361"},{"key":"120_CR6","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1002\/art.38851","volume":"66","author":"ME Weinblatt","year":"2014","unstructured":"Weinblatt ME, Genovese MC, Ho M, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014;66:3255\u201364.","journal-title":"Arthritis Rheumatol."},{"key":"120_CR7","unstructured":"Rigel to focus on ITP, DLE and dry eye strategy provides multiple paths to phase 3\/NDA in next 2-3 years. Rigel web site. http:\/\/ir.rigel.com\/phoenix.zhtml?c=120936&p=irol-newsArticle&id=1852213 . Accessed 5 March 2014."},{"key":"120_CR8","unstructured":"Fostamatinib (R788)\u2014ITP. Rigel web site. http:\/\/www.rigel.com\/rigel\/ITP . Accessed 5 March 2014."},{"key":"120_CR9","unstructured":"Rigel. Fostamatinib\u2014IgAN. Rigel web site. http:\/\/www.rigel.com\/rigel\/IgAN . Accessed 17 Oct 2014."},{"key":"120_CR10","doi-asserted-by":"crossref","first-page":"861481","DOI":"10.1155\/2009\/861481","volume":"2009","author":"AM Briggs","year":"2009","unstructured":"Briggs AM, March L, Lassere M, et al. Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database. Int J Rheumatol. 2009;2009:861481.","journal-title":"Int J Rheumatol."},{"key":"120_CR11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/VHRM.S2453","volume":"4","author":"C Turesson","year":"2008","unstructured":"Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag. 2008;4:605\u201314.","journal-title":"Vasc Health Risk Manag."},{"key":"120_CR12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.autrev.2009.02.015","volume":"8","author":"MT Nurmohamed","year":"2009","unstructured":"Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev. 2009;8:663\u20137.","journal-title":"Autoimmun Rev."},{"key":"120_CR13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/msc.112","volume":"5","author":"GJ Treharne","year":"2007","unstructured":"Treharne GJ, Douglas KM, Iwaszko J, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care. 2007;5:175\u201390.","journal-title":"Musculoskeletal Care."},{"key":"120_CR14","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1124\/dmd.30.11.1266","volume":"30","author":"JA Williams","year":"2002","unstructured":"Williams JA, Ring BJ, Cantrell VE, et al. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos. 2002;30:1266\u201373.","journal-title":"Drug Metab Dispos."},{"key":"120_CR15","volume-title":"Epidemiology of the rheumatic diseases","author":"AJ Silman","year":"2001","unstructured":"Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. 2nd ed. New York: Oxford University Press; 2001.","edition":"2"},{"key":"120_CR16","unstructured":"Centers for Disease Control and Prevention. Arthritis: NHIS Arthritis Surveillance. CDC website. http:\/\/www.cdc.gov\/arthritis\/data_statistics\/national_nhis.htm . Accessed 17 Dec 2013."},{"key":"120_CR17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/08998280.2001.11927781","volume":"14","author":"M Kuruvilla","year":"2001","unstructured":"Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proc (Bayl Univ Med Cent). 2001;14:305\u20136.","journal-title":"Proc (Bayl Univ Med Cent)."},{"key":"120_CR18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1872312811206030002","volume":"6","author":"SY Kim","year":"2012","unstructured":"Kim SY, Kang JY, Hartman JH, et al. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012;6:157\u201364.","journal-title":"Drug Metab Lett."},{"key":"120_CR19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2125.2011.04051.x","volume":"73","author":"S Lane","year":"2012","unstructured":"Lane S, Al-Zubiedi S, Hatch E, et al. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol. 2012;73:66\u201376.","journal-title":"Br J Clin Pharmacol."},{"key":"120_CR20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2013.10.022","volume":"232","author":"CM Ballantyne","year":"2014","unstructured":"Ballantyne CM, Hoogeveen RC, Raya JL, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study. Atherosclerosis. 2014;232:86\u201393.","journal-title":"Atherosclerosis."},{"key":"120_CR21","unstructured":"CRESTOR (rosuvastatin) [Summary of Product Characteristics]. Luton, UK: AstraZeneca UK Ltd. https:\/\/www.medicines.org.uk\/emc\/medicine\/11976 , 2013. Accessed 4 Mar 2015."},{"key":"120_CR22","unstructured":"ZOCOR (simvastatin) [Summary of Product Characteristics]. Hertfordshire, UK: Merck Sharp & Dohme Limited. https:\/\/www.medicines.org.uk\/emc\/medicine\/1201 , 2013. Accessed 4 Mar 2015."},{"key":"120_CR23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2012.163","volume":"92","author":"R Elsby","year":"2012","unstructured":"Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it\u2019s not just about OATP1B1. Clin Pharmacol Ther. 2012;92:584\u201398.","journal-title":"Clin Pharmacol Ther."},{"key":"120_CR24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","volume":"86","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86:197\u2013203.","journal-title":"Clin Pharmacol Ther."},{"key":"120_CR25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","volume":"78","author":"E Lee","year":"2005","unstructured":"Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330\u201341.","journal-title":"Clin Pharmacol Ther."},{"key":"120_CR26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","volume":"16","author":"MK Pasanen","year":"2006","unstructured":"Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16:873\u20139.","journal-title":"Pharmacogenet Genomics."},{"key":"120_CR27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","volume":"63","author":"M Niemi","year":"2011","unstructured":"Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157\u201381.","journal-title":"Pharmacol Rev."},{"key":"120_CR28","unstructured":"Center for Drug Evaluation and Research (CDER). Guidance for industry. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. U S Food and Drug Administration website. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf Accessed 22 Oct 2012."},{"key":"120_CR29","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","volume":"277","author":"World Medical Association declaration of Helsinki","year":"1997","unstructured":"World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925\u20136.","journal-title":"JAMA."},{"key":"120_CR30","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). International Conference on Harmonisation website. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf . Accessed 25 Mar 2014."},{"key":"120_CR31","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 2003;25:2553\u201363.","journal-title":"Clin Ther."},{"key":"120_CR32","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/pgs.09.85","volume":"10","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo JE, Pasanen MK, Neuvonen PJ, et al. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009;10:1617\u201324.","journal-title":"Pharmacogenomics."},{"key":"120_CR33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2125.2004.02095.x","volume":"58","author":"JJ Lilja","year":"2004","unstructured":"Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol. 2004;58:56\u201360.","journal-title":"Br J Clin Pharmacol."},{"key":"120_CR34","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40265-013-0072-9","volume":"73","author":"VM Alla","year":"2013","unstructured":"Alla VM, Agrawal V, DeNazareth A, et al. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Drugs. 2013;73:1025\u201354.","journal-title":"Drugs."},{"key":"120_CR35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1208\/s12248-009-9102-7","volume":"11","author":"A Grover","year":"2009","unstructured":"Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J. 2009;11:250\u201361.","journal-title":"AAPS J."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-015-0120-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-015-0120-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-015-0120-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T09:52:48Z","timestamp":1567504368000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-015-0120-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["120"],"URL":"https:\/\/doi.org\/10.1007\/s40268-015-0120-x","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,9]]}}}